Managed Account Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Managed Account Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$945K	Sell	15,020 -2,384	-14%	-$130K	﹤0.01%	2126
2015 Q1	$837K	Buy	17,404 +3,615	+26%	+$139K	﹤0.01%	2141
2014 Q4	$458K	Buy	+13,789	New	+$449K	﹤0.01%	2217
2014 Q3	–	Sell	-7,574	Closed	-$294K	–	2703
2014 Q2	$294K	Buy	7,574 +3,292	+77%	+$134K	﹤0.01%	2235
2014 Q1	$180K	Buy	+4,282	New	+$178K	﹤0.01%	2251

Other funds holding LGND

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Managed Account Advisors's LGND Position: Q2 2015 in Review

Managed Account Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 14% in Q2 2015, selling an estimated $130K and leaving 15,020 shares worth $945K. The position accounts for ﹤0.01% of the portfolio, ranked #2126.

Managed Account Advisors first reported a position in LGND in Q1 2014 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold LGND as of Q2 2015.

Managed Account Advisors held 15,020 shares of Ligand Pharmaceuticals worth $945K as of Q2 2015.
Managed Account Advisors sold 2,384 Ligand Pharmaceuticals shares in Q2 2015, an estimated $130K.
Ligand Pharmaceuticals made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2126 holding.
Managed Account Advisors first reported a position in Ligand Pharmaceuticals in Q1 2014 and has held it in 5 quarters since.
215 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.